Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. - Wikidata - wikimedia - TriplyDB

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

http://www.wikidata.org/entity/Q33780253

about

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals Lenalidomide and chronic lymphocytic leukemia Immune reconstitution in chronic lymphocytic leukemia Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies p73 as a pharmaceutical target for cancer therapy A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Molecular targets for selective killing of TRAIL-resistant leukemic cells.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53 The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Dose escalation of lenalidomide in relapsed or refractory acute leukemias.Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.Initial testing of lenalidomide by the pediatric preclinical testing program Targeting malignant B cells with an immunotoxin against ROR1 RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia.Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.Salvage therapy for relapsed chronic lymphocytic leukemia.Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Chronic lymphocytic leukemia: an update on biology and treatment.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.AdCD40L--crossing the valley of death?

P2860

Q24336378-163C9D09-8CDA-42A8-A688-BFCFAA955471 Q26823597-25862693-0E8B-4A06-B834-294B7977C9CD Q26865561-3A952E83-DF25-4813-9BBD-4428E0674EF3 Q27001318-683F4B92-0E57-4837-9D20-B1A37CEE3875 Q27674083-5FC84A6D-150F-499F-A049-9F7DB616DBF4 Q28478591-8DD70DC1-036D-4293-9AB8-F4890940E6AA Q28611414-560005C2-42CC-4150-96FD-9945A299E6D2 Q33391895-9DCBA44A-7CAC-4A50-81AE-30B62E51C0D4 Q33429161-413CBED9-0A75-4666-BD62-8C0480492E8A Q33796183-7C23F226-F495-4BD6-8A0E-87520FEACACE Q33891400-B1A361FE-5D99-47EB-89EE-051C1926041B Q33913537-0DDD8AB6-FE7F-47EC-8CFB-5B91A9E6AE94 Q34008584-7AA0A83F-5B45-44E8-A8EA-802A2E6F08C0 Q34009041-97205D1A-7707-449B-93AE-5FF35FFA22BA Q34137016-A3F2B837-0FAD-4EE3-B82A-6E1D5E57C27E Q34374056-E4A33749-2244-4580-9308-977F2835093B Q34488712-0E77032F-3270-4C72-9F50-F970F2B6A89A Q34534333-625261B7-3650-4EE4-97BD-89387B3A384F Q34625543-67AA7AA0-D1D4-4130-BB73-7C02A57635BD Q34923824-45C53C9E-7985-4C3A-B4E3-8A9A03327413 Q35146081-17AFDC5B-575F-4F3B-A9BA-DCF55EC65083 Q35202854-A4382438-1BA7-4E91-8753-6A2BC19B927A Q35839793-1A8F63A2-1323-45AF-8DCA-913D6A5BD545 Q35861457-A1A63939-854B-4A4C-8341-FAE065B8364F Q35969887-BB50F755-89A4-4BE6-AD87-F0CF907CE95B Q36010202-20D895B6-D0B8-4F82-8A67-A7ED3A9CFF63 Q36100977-BE9DF67B-66CF-4E4A-84B2-3C0978C1AED6 Q36118111-92C6BA9D-086D-401C-89A8-D001EBEB0446 Q36135185-C624F391-2719-41F3-935A-F0A53932BE19 Q36725307-46DB5F7E-9F6C-456F-A630-B04F347F0040 Q36920412-B21871E6-042B-4C45-8447-74800FB2B648 Q36929831-00523226-B56D-4D06-8C03-5B649109A508 Q37635605-514C5382-0F78-40F9-99A0-80E2753686C7 Q37865547-6F80303B-3C61-45ED-A492-626EAAEF739C Q37866334-BE9B6E0C-D86D-4CBA-B30F-F5406FB12C1E Q37874926-BD3A946E-EA35-4815-87CE-9D235A46268C Q37902948-3D842ED2-C2C3-465F-9BE6-38AF56DD1103 Q37910914-CEC5332A-5B0D-49FF-B6AB-9129B1AEA8AB Q37958036-0EE1E700-1FD2-4979-8C67-83F45590B7B9 Q38026926-FE0E2B03-7F82-4197-A162-B9A7FEC3E53D

P2860

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

http://www.wikidata.org/entity/Q33780253

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@ast

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@en

type

label

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@ast

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@en

prefLabel

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@ast

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@en

P1433

Q33780253-45BD9D2C-D490-49D1-9EC4-E019C6249CB5

P1476

Q33780253-F1ADC4C8-0B95-4919-A975-83FC30276EE9

P2093

Q33780253-04ABBE15-C549-4E67-82EF-51E4B0E6FE7E

Q33780253-194A5796-01FB-471B-8DA3-394EEC2C48CA

Q33780253-2BA7C4A3-9A5B-443F-82FF-574537842EEE

Q33780253-3A56BDEE-2404-4F90-8E20-20A8D16CE81F

Q33780253-3C0E1693-EB0C-47EE-8154-CA8BF97D3F47

Q33780253-4843F861-A1C1-49AC-9477-0B43ACEBF062

Q33780253-4A8BB48F-1148-43A6-8C63-68BEF7822C50

Q33780253-5F09E46B-D791-4463-B3A8-49F4958C9C02

Q33780253-6C816E68-A05A-40A9-9FD9-5A5152CB50B1

Q33780253-73848C5F-C60C-42D4-86DE-CDBBEA23EA70

P2860

Q33780253-063FAB0B-A311-474A-A011-8CDB740DD1F6

Q33780253-068F0D08-65CA-4A42-AF77-C008F75A5AF4

Q33780253-081EEC27-3C11-46D7-A193-D285BE9209D1

Q33780253-0B600205-EC7B-4CF5-A981-6B3A26C0BF72

Q33780253-0BA3D584-8A6A-4E4E-9289-36828EF57115

Q33780253-0BA8F855-287A-4EC5-A4CE-9D4D46400972

Q33780253-19D38CE2-6A37-4176-BE09-1A1B6DC3C941

Q33780253-2399F3A8-0704-4412-B991-C43B7E76B11C

Q33780253-23CBD67C-D4CF-4029-A73C-D38248BEC6D0

Q33780253-2490329E-D395-4280-9231-D6E550E831A7

P304

Q33780253-B134050D-050A-45F4-AB2E-270C7267C288

P31

Q33780253-D52847AB-3014-4F25-AE69-93A0676190F7

P356

Q33780253-118C86D2-1DB2-454C-9C29-20C13AE9E924

P407

Q33780253-2F1BD4D0-4B61-467D-8B56-551930121E8F

P433

Q33780253-281D55BE-AB32-47DD-B352-792C2F641B27

P478

Q33780253-B7BDDD02-1961-4505-B39B-9EDD36FFFD91

P50

Q33780253-E8D41972-D539-492F-A52C-913EBC5B144F

P577

Q33780253-15003F8C-01D1-4829-AE6D-9BF5AA8DA8EC

P5875

Q33780253-D8B61214-F107-4DE7-A6C5-2FF420AF5BA7

P698

Q33780253-ECF2DB99-84D1-4B77-AED7-4015A72BB1F4

P921

Q33780253-D22F111B-C90B-432C-8729-33A630480300

P932

Q33780253-FC2A9391-F997-4966-ABDF-94E63F1CC4E4

P356

BLOOD-2009-09-242438

P1433

P1476

Lenalidomide treatment promote ...... PI3-kinase-dependent pathway.

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Amy Lehman

http://www.w3.org/2001/XMLSchema#string

Asha Ramanunni

http://www.w3.org/2001/XMLSchema#string

Chelsey A Raymond

http://www.w3.org/2001/XMLSchema#string

Ching-Shih Chen

http://www.w3.org/2001/XMLSchema#string

Christoph Rader

http://www.w3.org/2001/XMLSchema#string

David Jarjoura

http://www.w3.org/2001/XMLSchema#string

Kristie A Blum

http://www.w3.org/2001/XMLSchema#string

Lan V Pham

http://www.w3.org/2001/XMLSchema#string

Leslie Andritsos

http://www.w3.org/2001/XMLSchema#string

P2860

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

Stem cell transplantation in chronic lymphocytic leukemia

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Efficacy of lenalidomide in myelodysplastic syndromes.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Post-transcriptional regulation in lymphocytes: the case of CD154

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

P304

2619-2629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-09-242438

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40452611

http://www.w3.org/2001/XMLSchema#string

P698

19965642

http://www.w3.org/2001/XMLSchema#string

P921

P932

2852364

http://www.w3.org/2001/XMLSchema#string